Eisai Submits Aricept VaD sNDA; Study Criteria Endorsed By Committee
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Eisai/Pfizer are looking to expand Aricept’s approved indications to include vascular dementia based on two studies that enrolled patients using NINDS-AIREN diagnosis criteria.
You may also be interested in...
Eisai Aricept "not approvable" for VaD
Eisai/Pfizer's Alzheimer's therapy Aricept (donepezil) is "not approvable" for vascular dementia claim, FDA says July 3. FDA found that the application contained insufficient information to support an approval at this time, the firm said. Eisai plans to have discussions with FDA as to the next regulatory step. FDA's Peripheral & Central Nervous System Drugs Advisory Committee was scheduled to review the sNDA May 16, but the meeting was cancelled. At a March 2001 meeting, the committee had debated whether VaD was a distinct clinical entity. Aricept is the first agent to be filed for VaD, but Janssen's Reminyl (galantamine) and Novartis' Exelon (rivastigmine) are both in Phase III for the condition (1Pharmaceutical Approvals Monthly Oct. 1, 2002, p. 23
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product